首页> 外文期刊>Journal of Hainan Medical University >Clinical study that preoperative intracavitary radiotherapy combined with neoadjuvant chemotherapy promotes apoptosis in IIa and IIb cervical cancer tissue
【24h】

Clinical study that preoperative intracavitary radiotherapy combined with neoadjuvant chemotherapy promotes apoptosis in IIa and IIb cervical cancer tissue

机译:术前腔内放疗联合新辅助化疗促进IIa和IIb子宫颈癌组织凋亡的临床研究

获取原文
           

摘要

Objective: To study the effect of preoperative intracavitary radiotherapy combined withneoadjuvant chemotherapy on apoptosis in IIa and IIb cervical cancer tissue. Methods:Patients with IIa and IIb locally advanced cervical cancer who received preoperative auxiliarytherapy in our hospital between May 2013 and December 2016 were retrospectively analyzedand divided into adjuvant chemotherapy group, intracavitary radiotherapy group and combinedtreatment group according to the different preoperative adjuvant therapies. Cervical cancertissues were collected respectively during biopsy (before treatment) and during surgicalexcision (after treatment) to extract RNA, and then fluorescence quantitative PCR kits wereused to determine the expression of pro-apoptosis genes, anti-apoptosis genes and invasiongenes. Results: After treatment, SARI, Rab26, FHIT and eIF4E3 expression in cervical cancerlesions of three groups were significantly higher than those before treatment while serumCA125, TSGF and SCC-Ag levels as well as MRP8, MRP14, p38MAPK, ERK1/2 and c-mycexpression were significantly lower than those before treatment, and SARI, Rab26, FHIT andeIF4E3 expression in cervical cancer lesions of combined treatment group were significantlyhigher than those of adjuvant chemotherapy group and intracavitary radiotherapy group whileserum CA125, TSGF and SCC-Ag levels as well as MRP8, MRP14, p38MAPK, ERK1/2and c-myc expression were significantly lower than those of adjuvant chemotherapy groupand intracavitary radiotherapy group. Conclusion: Preoperative intracavitary radiotherapycombined with neoadjuvant chemotherapy can promote apoptosis in IIa and IIb cervical cancertissue.
机译:目的:探讨术前腔内放疗联合新辅助化疗对宫颈癌IIa和IIb细胞凋亡的影响。方法:回顾性分析2013年5月至2016年12月在我院接受术前辅助治疗的IIa和IIb局部晚期宫颈癌患者,并根据术前辅助治疗方法分为辅助化疗组,腔内放疗组和联合治疗组。分别在活检(治疗前)和手术切除(治疗后)期间收集宫颈癌组织以提取RNA,然后使用荧光定量PCR试剂盒确定促凋亡基因,抗凋亡基因和侵袭基因的表达。结果:治疗后,三组宫颈癌中SARI,Rab26,FHIT和eIF4E3的表达均显着高于治疗前,而血清CA125,TSGF和SCC-Ag以及MRP8,MRP14,p38MAPK,ERK1 / 2和c-菌丝表达明显低于治疗前,联合治疗组宫颈癌病灶中的SARI,Rab26,FHIT和eIF4E3表达明显高于辅助化疗组和腔内放疗组,而血清CA125,TSGF和SCC-Ag以及MRP8 MRP14,p38MAPK,ERK1 / 2和c-myc的表达明显低于辅助化疗组和腔内放疗组。结论:术前腔内放疗联合新辅助化疗可促进宫颈癌IIa和IIb细胞凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号